Drugs / BYON3521
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05323045 | Mar 2022 → Mar 2024 | cancer | Byondis B.V. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-12 | Byondis B.V. | Results Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics byondis.com ↗
The data from in vitro and in vivo studies showed that BYON3521 potently and selectively kills tumor cells expressing c-MET, even at low c-MET-expressing levels. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-12 | Byondis B.V. | Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics byondis.com ↗ |
| 2022-08-25 | Byondis B.V. | Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521 byondis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BYON3521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05323045 ↗ |
| Modality | Monoclonal antibody | “BYON3521 is a novel site-specifically conjugated duocarmycin-based antibody-drug conjugate (ADC), comprising a humanized cysteine-engineered IgG1 monoclonal antibody” PMID 37042205 ↗ Jun 2023 |
| Route | Intravenous | “BYON3521 (in the vein) infusion every three weeks.” NCT05323045 ↗ |
| Target | MET | “towards both human and cynomolgus MET” PMID 37042205 ↗ Jun 2023 |